Researchers to study experimental breast cancer vaccine

Cancer Center researchers led by Michael DeGregorio, professor of hematology and oncology, launched a study of a new, experimental vaccine to determine if it can arrest or prevent breast cancer when used in conjunction with standard hormonal therapies. The vaccine, Stimuvax®, aims to stimulate the immune system to target and destroy breast-cancer tumors. Results from the UC Davis study, which is funded with a $3 million grant from Merck KGaA, will help direct the design of human clinical trials slated to begin worldwide this year.